{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back
Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
Questionnaire
  1. According to you which is the most important factor which predicts the risk of hypertension among Indians? *
  2. According to you which are the current need gaps in antihypertensive therapy? *
    3. Need gap in patient education/knowledge
    Need gap access to treatment
    Systemic/Policy Gap
    Clinical/Service gap
  3. How many patients present with newly detected hypertension in your clinical practice in a month? *

  4. How effective do you find Olmesartan in achieving target blood pressure (BP) levels in hypertensive patients? *

  5. How often do you prescribe Olmesartan as a first-line antihypertensive therapy? *

  6. In your experience, how well does Olmesartan maintain consistent BP control over 24 hours? (Please specify) *
  7. How would you rate your patient adherence to Olmesartan therapy? (On scale of 0-10 with 0 being no adherence and 10 being complete adherence) *
  8. Compared to other ARBs (Angiotensin Receptor Blockers), how would you rate Olmesartan’s efficacy in BP control? *

  9. How would you rate the evidence supporting Olmesartan’s vascular protective effects in context of the VIOS trial? *

  10. How important is Olmesartan’s vascular protective effect in your decision to prescribe it? *

  11. How convinced are you regarding vascular protective effects (e.g., improved endothelial function) with Olmesartan use? *

  12. What is the most common patient population you prescribe Olmesartan to? *

  13. How would you rate Olmesartan’s tolerability among your patients? *

  14. What is the most common side effect you observe with Olmesartan? *

  15. How often do you encounter Olmesartan-related hyperkalemia in your practice? *

  16. How confident are you in Olmesartan’s safety profile for long-term use? *

  17. Have you encountered any specific patient populations where Olmesartan's side effects are more pronounced? (Please specify) *
  18. How confident are you in Olmesartan’s ability to provide 24-hour long BP control? *

  19. What proportion of your hypertensive patients are on combination therapy with Olmesartan? *

  20. How effective is Olmesartan in patients with resistant hypertension? *

  21. How effective is Olmesartan in managing BP in patients with diabetes?*

  22. How do you perceive Olmesartan’s role in patients with diabetes and coexisting chronic kidney disease (CKD) in context of the ROADMAP trial? *
  23. How frequently do you monitor renal function in patients on Olmesartan? *

  24. How effective is Olmesartan in reducing left ventricular hypertrophy (LVH) in hypertensive patients? *

  25. How often do you use Olmesartan in patients with a history of stroke? *

  26. How much time is generally required to optimally titrate Olmesartan dosage to achieve adequate BP control? *

  27. How significant is Olmesartan’s role in preventing target organ damage? *

  28. How often do you prefer Olmesartan therapy in your patients with obesity? *

  29. How well does Olmesartan perform in patients with metabolic syndrome? *

  30. How often do patients discontinue Olmesartan due to side effects? *

  31. How do you typically approach LDL-C target setting in patients with multiple cardiovascular risk factors but no prior ASCVD? *
  32. What are your main considerations when choosing between high-intensity statin monotherapy vs. statin plus ezetimibe in secondary prevention? *
  33. In your experience, what are the most common barriers to achieving guideline-recommended LDL-C goals in high-risk patients? *
  34. How do you assess cardiovascular risk when considering lipid-lowering therapy in your patients without prior ASCVD? *
  35. Which risk assessment tool do you use most commonly for primary prevention? *

  36. In your practice, how often do you re-evaluate LDL-C levels after initiating or modifying lipid-lowering therapy? *
  37. When initiating lipid-lowering therapy in a patient with ASCVD, your most common first-line approach is: *

  38. What LDL-C reduction goal do you typically target in secondary prevention patients? *

  39. In primary prevention, when do you consider adding ezetimibe to statin therapy? *

  40. How often do patient preferences or concerns (e.g., fear of side effects) influence your choice of lipid-lowering therapy? *
  41. Describe your strategy for managing statin intolerance in patients with established CVD. *
  42. What is your opinion on the evolving role of ezetimibe in patients who do not meet LDL-C targets despite maximum tolerated statin therapy? *
  43. For patients at very high risk (e.g., recent MI), how often do you prescribe combination therapy upfront (statin + ezetimibe)? *

  44. When intensifying therapy, what do you prioritize? *

  45. In your experience what proportion of patients reach their LDL-C targets on statin monotherapy alone? *

  46. How frequently do you prescribe ezetimibe in clinical practice? *

  47. When patients do not achieve LDL-C goals despite statin + ezetimibe, what is your next step? *

  48. Do you routinely document statin tolerance in the EHR? *

  49. Which patient population do you find most challenging to manage for dyslipidemia? *

  50. Do you believe ezetimibe significantly improves long-term cardiovascular outcomes in real-world settings? *